Relay Therapeutics (RLAY) – Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Relay Therapeutics (NASDAQ: RLAY):

• 8/20/2026 – Relay Therapeutics was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/20/2026 – Relay Therapeutics had its price target raised by HC Wainwright from $28.00 to $29.00. They now have a “buy” rating on the stock.
• 8/15/2026 – Relay Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/14/2026 – Relay Therapeutics had its price target raised by JPMorgan Chase & Co. from $28.00 to $31.00. They now have an “overweight” rating on the stock.
• 8/10/2026 – Relay Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/10/2026 – Relay Therapeutics had its price target raised by Citizens Jmp from $21.00 to $26.00. They now have a “market outperform” rating on the stock.
• 8/7/2026 – Relay Therapeutics had its price target raised by Barclays PLC from $27.00 to $30.00. They now have an “overweight” rating on the stock.
• 8/7/2026 – Relay Therapeutics had its “buy” rating reaffirmed by Guggenheim.
• 7/22/2026 – Relay Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/21/2026 – Relay Therapeutics had its price target raised by The Goldman Sachs Group, Inc. from $22.00 to $31.00. They now have a “buy” rating on the stock.
• 7/16/2026 – Relay Therapeutics is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $29.00 price target on the stock.
• 7/16/2026 – Relay Therapeutics is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $29.00 price target on the stock.
• 7/8/2026 – Relay Therapeutics is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $28.00 price target on the stock.
• 7/6/2026 – Relay Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Activity at Relay Therapeutics

In other Relay Therapeutics news, insider Peter Rahmer sold 50,000 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $19.09, for a total transaction of $954,500.00. Following the completion of the sale, the insider directly owned 225,857 shares in the company, valued at $4,311,610.13. This represents a 18.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Thomas Catinazzo sold 187,163 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $16.97, for a total value of $3,176,156.11. Following the transaction, the chief financial officer directly owned 177,461 shares in the company, valued at $3,011,513.17. This trade represents a 51.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 6,414,147 shares of company stock worth $123,723,695 in the last 90 days. Corporate insiders own 5.04% of the company’s stock.

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.